Genetic Variants in Linear Localized Scleroderma (NCT02222038) | Clinical Trial Compass
CompletedNot Applicable
Genetic Variants in Linear Localized Scleroderma
Switzerland50 participantsStarted 2014-08
Plain-language summary
The purpose of this study is to investigate the genetic architecture of Linear Localized Scleroderma (LLS) (linear morphea) by whole exome sequencing.
Who can participate
Age range5 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male or female subjects ≥ 5 years of age with well phenotyped LLS
* Affecting their head and / or face "termed " en coup de sabre " type LLS or Hemiatrophia faciei or Parry-Romberg syndrome, with or without therapy
* Affecting any site of the body except the head or face, with or without therapy
Exclusion Criteria:
* Patients with signs of systemic scleroderma
* Patients with localized scleroderma (morphea) other than the linear type ("plaque-type", "morphea profunda", "generalized morphea") Patients with diagnosed gadolinium induced scleroderma Patients with post-irradiation scleroderma Patients with missing consent
What they're measuring
1
number of key genes /number of mutations in LLS (localized linear scleroderma)